93103-15-2Relevant articles and documents
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors
Heppner, David E.,Günther, Marcel,Wittlinger, Florian,Laufer, Stefan A.,Eck, Michael J.
, p. 4293 - 4305 (2020/05/27)
Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism. To dissect the molecular basis for their activity, we determined the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallography. These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the "αC-helix out" inactive state. Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant. Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.
Syntheses of 2-mercapto-4-substituted imidazole derivatives with antiinflammatory properties
Maeda,Suzuki,Iwasaki,Matsumoto,Iwasawa
, p. 2536 - 2543 (2007/10/02)
-